Meden Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 24 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 38.41%
(FY 2023)
- Profit 86.09%
(FY 2023)
- Ebitda 67.72%
(FY 2023)
- Net Worth 63.13%
(FY 2023)
- Total Assets 41.23%
(FY 2023)
About Meden Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vikash Agarwal and Nathmal Agarwal serve as directors at the Company.
- CIN/LLPIN
U51397MH2000PTC129691
- Company No.
129691
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Meden Pharma Private Limited offer?
Meden Pharma Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Emulsifiers, Medical Laboratory Instruments, VTM Kit Raw Materials.
Who are the key members and board of directors at Meden Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikash Agarwal  | Director | 02-Apr-2006 | Current |
| Nathmal Agarwal | Director | 21-Nov-2000 | Current |
Financial Performance of Meden Pharma.
Meden Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 38.41% increase. The company also saw a substantial improvement in profitability, with a 86.09% increase in profit. The company's net worth Soared by an impressive increase of 63.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meden Pharma?
Unlock access to Meden Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kks Fabrics Private LimitedActive 11 years 9 monthsVikash Agarwal and Nathmal Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meden Pharma?
Unlock and access historical data on people associated with Meden Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meden Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meden Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
